table for its ability to act as a 5HT1-A agonist. In addition, ziprasidone is thought to bind almost exclusively in the A10 mesolimbic/mesocortical pathway and to avoid the A9 nigrostriatal pathway in the brain. 4 Thus, akathisia would not be expected to be a frequent occurrence with this medication.
Nonetheless, after a year in the market, I and other clinicians with whom I have regular contact have seen patients develop on rare occasions a level of agitation that has been confusing. Just what this represents is controversial. Some have proposed that it is anxiety, while others have hypothesized a "serotonin syndrome."
My hypothesis is that what we are seeing is "psychic akathisia," a term not yet in the literature but appropriately descriptive of the phenomenon. All antipsychotics can cause akathisia, 5, 6 but because of ziprasidone's minimal or absent binding in a motor pathway (the A9 pathway), the patient experiences this almost exclusively as a subjective restlessness and agitation.
I have found that treating the problem as though it is akathisia is generally therapeutic. Interventions have included beta blockers, benzodiazepines (rarely very helpful), cyproheptadine, 7 and most recently donepezil, 8 under the theory that altering the ratio of dopamine and acetylcholine in the brain may be more important in the etiology of akathisia than the absolute amount of either neurotransmitter itself.
Further study of this issue is warranted and encouraged as we all strive to do better in treating some of medicine's most challenging patients. 
